An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

In cardiovascular news, AstraZeneca’s experimental drug AZD0780 showed promising results in a Phase IIb trial, significantly reducing LDL cholesterol levels. These recent developments highlight ...

In cardiovascular news, AstraZeneca’s experimental drug AZD0780 showed promising results in a Phase IIb trial, significantly reducing LDL cholesterol levels. These recent developments highlight ...

The company said recently it is moving "at pace" with AZD0780 into the next stage of development, with a phase 2b trial ongoing and data expected in the first half of 2025, as it builds a pipeline ...